Perform hepatitis C genotype prior to initiation of therapy.
Test for presence of virus with NS5A resistance-associated polymorphisms in patients with genotype 1a infection prior to initiation.
Screen all patients of HBV infection prior to use.
Perform hepatic function testing prior to therapy at treatment week 8, 12, and as clinically indicated.
Monitor clinical and laboratory signs of hepatitis flare or HBV reactivation in patients with evidence of current or prior HBV infection during treatment and post-treatment follow-up.